This week, we introduce a new episode for our myeloma series, this time focusing on risk stratification and response criteria. The initial workup and surveillance labs are expansive, but all of the studies we do have a purpose. Many present-day studies also use “minimal residual disease” (MRD) testing. What does this mean? How do we use this?We go through all of this and more in this incredibly high yield episode. Content:- How do we risk stratify patients with newly diagnosed MM? - What are the criteria used to risk stratify? Why does this matter?- How do we define response to treatment? Progression?- What is the role of "minimal residual disease" in myeloma? ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related